{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:14:33Z","timestamp":1793463273092,"version":"4.5.0"},"reference-count":160,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2010,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1111\/j.1439-0507.2009.01820.x","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T13:42:50Z","timestamp":1260538970000},"page":"95-113","source":"Crossref","is-referenced-by-count":64,"title":["Clinically relevant drug interactions of current antifungal agents"],"prefix":"10.1111","volume":"53","author":[{"given":"Paul O.","family":"Gubbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Heldenbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30\u2003years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB3","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1517\/14656566.6.13.2231","article-title":"Drug-drug interactions of antifungal agents and implications for patient care","volume":"6","author":"Gubbins","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1128\/AAC.48.3.815-823.2004","article-title":"Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/dmd.104.003244","article-title":"Hepatic uptake of the novel antifungal agent caspofungin","volume":"33","author":"Sandhu","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB7","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0090-9556(24)15072-6","article-title":"Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine","volume":"28","author":"Balani","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/0091270005279580","article-title":"Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction","volume":"45","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.27.3.369","article-title":"The echioncandins","volume":"27","author":"Cappelletty","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1592\/phco.27.1.53","article-title":"Micafungin: a new echinocandin antifungal","volume":"27","author":"Joseph","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/AAC.01279-08","article-title":"In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome p450 interactions of anidulafungin","volume":"53","author":"Damle","year":"2009","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1592\/phco.29.1.17","article-title":"Pharmacology and antifungal properties of anidulafungin, a new echinocandin","volume":"29","author":"Estes","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB14","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB15","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1128\/AAC.42.7.1592","article-title":"Glucuronidation of 3_-azido-3_-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, and valproic acid","volume":"42","author":"Trapnell","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P-glycoprotein","volume":"46","author":"Wang","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.037549","article-title":"Interaction of cytochrome P450 3A inhibitors with P-glycoprotein","volume":"303","author":"Yasuda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1 Suppl.","key":"10.1111\/j.1439-0507.2009.01820.x-BIB19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: an overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/dkg089","article-title":"A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution","volume":"51","author":"Johnson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","article-title":"Effect of food on the pharmacokinetics of a new hydroxypropyl-\u03b2-cyclodextrin formulation of itraconazole","volume":"16","author":"Van de Velde","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1875-9114.1998.tb03856.x","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers","volume":"18","author":"Barone","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB23","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1128\/AAC.42.7.1862","article-title":"Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers","volume":"42","author":"Barone","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","article-title":"Optimisation of itraconazole therapy using target drug concentrations","volume":"35","author":"Poirier","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/dmd.105.008508","article-title":"stereochemical aspects of itraconazole metabolism in vitro and in vivo","volume":"34","author":"Kunze","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB29","doi-asserted-by":"crossref","first-page":"12897","DOI":"10.1074\/jbc.271.22.12897","article-title":"The role of passive transbilayer drug movement in multidrug resistance and its modulation","volume":"271","author":"Eytan","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1432-1327.2000.01046.x","article-title":"Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane","volume":"267","author":"Fert\u00e9","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB31","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/jps.20963","article-title":"Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)","volume":"96","author":"Gupta","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB32","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1111\/j.1439-0507.2009.01820.x-BIB33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"Suppl. 1","key":"10.1111\/j.1439-0507.2009.01820.x-BIB35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1470-9465.2004.00838.x","article-title":"Voriconazole: a new therapeutic agent with an extended spectrum of antifungal activity","volume":"10","author":"Donnelly","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.1365-2141.1997.972911.x","article-title":"Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia","volume":"97","author":"Schwartz","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB37","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB39","volume-title":"Pharmacokinetics, Safety, and Tolerability of Voriconazole in Hospitalized Children","author":"Walsh","year":"2006"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB40","volume-title":"Population Pharmacokinetic (POP-PK) Analysis of Voriconazole (VRC): Developing a Rationale for Dosage in Pediatric Patients","author":"Walsh","year":"2007"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"1 Suppl.","key":"10.1111\/j.1439-0507.2009.01820.x-BIB42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2003.01998.x","article-title":"Voriconazole does not affect the steady-state pharmacokinetics of digoxin","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB43","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB45","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB47","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers","volume":"50","author":"Sansone-Parsons","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB48","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB49","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/jac\/dkn409","article-title":"Posaconazole concentrations in the central nervous system","volume":"62","author":"R\u00fcping","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB50","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/AAC.00472-06","article-title":"Effects of age, gender, race\/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers","volume":"51","author":"Sansone-Parsons","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB54","first-page":"831","article-title":"Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone","volume":"103","author":"Chung","year":"1971","journal-title":"Am Rev Respir Dis"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000007260","article-title":"Flucytosine: correlation between toxicity and pharmacokinetic parameters","volume":"46","author":"Vermes","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00007691-200012000-00006","article-title":"Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM","volume":"22","author":"Vermes","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB59","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QCO.0b013e3282f1be91","article-title":"Mould active azoles: pharmacokinetics, drug interactions in neutropenic hosts","volume":"20","author":"Gubbins","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1385\/1-59259-924-9:289","volume-title":"Drug Interactions in Infectious Diseases","author":"Gubbins","year":"2005"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB62","first-page":"511","article-title":"The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"82","author":"Olkkola","year":"1996","journal-title":"Anesth Analg"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s002280050223","article-title":"Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam","volume":"51","author":"Ahonen","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clinthera.2009.02.022","article-title":"Effects of oral posaconazole on the pharmacokinetics of oral and intravenous midazoloam: a phase I randomized, open-label, crossover study in healthy volunteers","volume":"31","author":"Krishna","year":"2009","journal-title":"Clin Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB66","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.1994.184","article-title":"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole","volume":"56","author":"Varhe","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB67","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0009-9236(96)90059-4","article-title":"The effect of ingestion time interval on the interaction between itraconazole and triazolam","volume":"60","author":"Neuvonen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB68","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2125.1996.03189.x","article-title":"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism","volume":"41","author":"Varhe","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2125.1996.tb00009.x","article-title":"Effect of fluconazole dose on the extent of fluconazole-triazolam interaction","volume":"42","author":"Varhe","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB70","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"79","author":"Saari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB71","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1472-8206.1996.tb00312.x","article-title":"The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam","volume":"10","author":"Ahonen","year":"1996","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB72","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-007-0350-0","article-title":"Voriconazole and fluconazole increase the exposure to oral diazepam","volume":"63","author":"Saari","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB73","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00007691-199604000-00003","article-title":"Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam","volume":"18","author":"Ahonen","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00228-003-0681-4","article-title":"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers","volume":"59","author":"Oda","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200206000-00008","article-title":"No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam","volume":"24","author":"Otsuji","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0009-9236(97)90038-2","article-title":"Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole","volume":"62","author":"Kivist\u00f6","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbmt.2005.10.022","article-title":"Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients","volume":"12","author":"Leather","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB78","first-page":"271","article-title":"Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients","volume":"46","author":"Billaud","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB79","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mcp.2002.121911","article-title":"Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients","volume":"71","author":"Romero","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB80","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","article-title":"Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes","volume":"46","author":"Venkataramanan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/ndt\/gfh593","article-title":"Interaction between voriconazole and tacrolimus in a kidney-transplanted patient","volume":"20","author":"Tintillier","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl. 10","key":"10.1111\/j.1439-0507.2009.01820.x-BIB82","first-page":"164","article-title":"Immunosuppressive drug interactions with anti-infective agents","volume":"4","author":"Anonymous","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007691-199708000-00013","article-title":"Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro","volume":"19","author":"Omar","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB84","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00007890-199405270-00022","article-title":"Fluconazole therapy in transplant recipients receiving FK506","volume":"57","author":"Ma\u00f1ez","year":"1994","journal-title":"Transplantation"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB85","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jac\/24.5.781","article-title":"Absence of significant interaction of fluconazole with cyclosporin","volume":"24","author":"Kr\u00fcger","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB86","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00007890-199105000-00016","article-title":"Interaction between cyclosporine and fluconazole in renal allograft recipients","volume":"51","author":"Canafax","year":"1991","journal-title":"Transplantation"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB87","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/106002809302700405","article-title":"Fluconazole-cyclosporine interaction: a dose-dependent effect?","volume":"27","author":"L\u00f3pez-Gil","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB88","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00007890-199604270-00026","article-title":"Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients","volume":"61","author":"Osowski","year":"1996","journal-title":"Transplantation"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB89","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1592\/phco.27.6.825","article-title":"Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus","volume":"27","author":"Sansone-Parsons","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB90","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/01.TP.0000147462.86886.F3","article-title":"Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient","volume":"79","author":"Kuypers","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB91","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1592\/phco.26.2.289","article-title":"Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient","volume":"26","author":"Said","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB92","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/00007890-200211270-00024","article-title":"Fluconazole-sirolimus drug interaction","volume":"27","author":"Cervelli","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB93","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"Saad","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB94","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.transproceed.2004.09.043","article-title":"Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases","volume":"36","author":"Mathis","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB95","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1016\/j.transproceed.2004.10.056","article-title":"Clinical relevance of sirolimus drug interactions in transplant patients","volume":"36","author":"Sadaba","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB96","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2005.12.032","article-title":"Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Marty","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB97","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1592\/phco.28.6.719","article-title":"Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management","volume":"28","author":"Surowiec","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB98","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/03007990802644209","article-title":"Effects of oral posaconazole on the pharmacokinetics of sirolimus","volume":"25","author":"Moton","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB99","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0009-9236(98)90066-2","article-title":"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole","volume":"64","author":"Varis","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB101","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0773.1999.tb01059.x","article-title":"Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers","volume":"85","author":"Varis","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB102","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1067\/mcp.2000.110772","article-title":"The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect","volume":"68","author":"Varis","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002280050720","article-title":"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone","volume":"56","author":"Varis","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB104","volume-title":"The Pharmacokinetics of Voriconazole and its Effect on Prednisolone Disposition","author":"Ghahramani","year":"2000"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1067\/mcp.2002.127397","article-title":"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole","volume":"72","author":"Raaska","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB106","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000095941","article-title":"Systemic levels of inhaled fluticasone in lung transplant recipients","volume":"74","author":"Naef","year":"2007","journal-title":"Respiration"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB107","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB108","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0009-9236(96)90167-8","article-title":"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid","volume":"60","author":"Neuvonen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB109","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","article-title":"Effect of itraconazole on the pharmacokinetics of atorvastatin","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB111","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1067\/mcp.2000.110537","article-title":"Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin","volume":"68","author":"Mazzu","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.1998.00034.x","article-title":"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin","volume":"46","author":"Kivist\u00f6","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB113","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1023\/A:1011077109233","article-title":"Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions","volume":"18","author":"Ishigam","year":"2001","journal-title":"Pharm Res"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB114","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","article-title":"Effect of itraconazole on the pharmacokinetics of rosuvastatin","volume":"73","author":"Cooper","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002280000127","article-title":"Effect of fluconazole on plasma fluvastatin and pravastatin concentrations","volume":"56","author":"Kantola","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB116","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-002-0508-8","article-title":"Effect of fluconazole on the pharmacokinetics of rosuvastatin","volume":"58","author":"Cooper","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB117","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.1C467","article-title":"Simvastatin-fluconazole causing rhabdomyolysis","volume":"37","author":"Shaukat","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB118","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0027-9684(15)31280-3","article-title":"Rhabdomyolysis induced by simvastatin-fluconazole combination","volume":"100","author":"Hazin","year":"2008","journal-title":"J Natl Med Assoc"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB119","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-004-0858-5","article-title":"Rhabdomyolysis in a patient receiving atorvastatin and fluconazole","volume":"60","author":"Kahri","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB120","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB121","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0090-9556(24)15273-7","article-title":"Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver","volume":"27","author":"Jacobsen","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB122","first-page":"146","article-title":"Drug-drug interactions with newer antiretroviral agents","volume":"16","author":"Aberg","year":"2008","journal-title":"Top HIV Med"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB123","first-page":"1104","article-title":"Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir","volume":"25","author":"Cato","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB124","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.0306-5251.2001.01409.x","article-title":"The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals","volume":"51","author":"Koks","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB126","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB127","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/00912700122009728","article-title":"Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors","volume":"41","author":"von Moltke","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","article-title":"Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans","volume":"72","author":"Mouly","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB129","first-page":"73","article-title":"Voriconazole and efavirenz at steady state in healthy male subjects","volume":"48","author":"Liu","year":"2008","journal-title":"J Clin Phamacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.2007.03085.x","article-title":"Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers","volume":"65","author":"Damle","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB131","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/bmj.301.6753.669-b","article-title":"Potentiation of action of warfarin by itraconazole","volume":"301","author":"Yeh","year":"1990","journal-title":"BMJ"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB132","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies","volume":"24","author":"Black","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB133","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.2008.150","article-title":"Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding","volume":"84","author":"Schelleman","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1439-0507.2009.01820.x-BIB134","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","article-title":"Voriconazole potentiates warfarin-induced prothrombin time prolongation","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB135","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.49","article-title":"Effect of fluconazole on disposition of phenytoin","volume":"49","author":"Blum","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1439-0507.2009.01820.x-BIB136","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB137","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1185\/030079907X187937","article-title":"Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB138","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0006-291X(92)91593-F","article-title":"The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin","volume":"189","author":"de Lannoy","year":"1992","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB139","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-199712000-00001","article-title":"Itraconazole decreases renal clearance of digoxin","volume":"19","author":"Jalava","year":"1997","journal-title":"Ther Drug Monit"},{"issue":"Suppl. 1","key":"10.1111\/j.1439-0507.2009.01820.x-BIB140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2003.01998.x","article-title":"Voriconazole does not affect the steady-state pharmacokinetics of digoxin","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB141","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mph.0000172751.06286.5b","article-title":"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature","volume":"27","author":"Burm\u00fadez","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB142","first-page":"33","article-title":"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma","volume":"28","author":"Bashir","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB143","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e318030d289","article-title":"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia","volume":"29","author":"Mantadakis","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB144","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPH.0b013e31819b9d01","article-title":"Posaconazole-increased vincristine neurotoxicity in a child: a case report","volume":"31","author":"Eiden","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/pbc.21786","article-title":"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X","volume":"52","author":"Porter","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB146","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","article-title":"Potential for interactions between caspofungin and nelfinavir or rifampin","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB147","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-199936030-00004","article-title":"Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications","volume":"36","author":"Fleisher","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB148","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1081\/DMR-120026871","article-title":"Clinical relevance of P-glycoprotein in drug therapy","volume":"35","author":"Lin","year":"2003","journal-title":"Drug Metab Rev"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB149","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","article-title":"Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity","volume":"7","author":"Lim","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2710.2005.00632.x","article-title":"Reduced oral itraconazole bioavailability by antacid suspension","volume":"30","author":"Lohinavy","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB151","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/j.1875-9114.1994.tb02847.x","article-title":"Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers","volume":"14","author":"May","year":"1994","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB152","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/bdd.296","article-title":"Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole","volume":"23","author":"Damle","year":"2002","journal-title":"Biopharm Drug Disp"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB153","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB154","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB155","first-page":"2655","article-title":"Voriconazole in the treatment of invasive aspergillosis","volume":"18","author":"Muijser","year":"2002","journal-title":"Drugs"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB156","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-199309040-00008","article-title":"Possible interaction between phenobarbital, carbamazepine and itraconazole","volume":"9","author":"Bonay","year":"1993","journal-title":"Drug Saf"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB157","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0009-9236(95)90017-9","article-title":"Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin","volume":"58","author":"Ducharme","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB158","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002280050437","article-title":"Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB159","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079906X167507","article-title":"Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1439-0507.2009.01820.x-BIB160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1991.tb03718.x","article-title":"Induction of fluconazole metabolism by rifampin: in vivo study in humans","volume":"31","author":"Apseloff","year":"1991","journal-title":"J Clin Pharmacol"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2009.01820.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1439-0507.2009.01820.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T19:35:43Z","timestamp":1739475343000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2009.01820.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":160,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2009.01820.x","relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}